ArcticStartup’s Post

With #JPM2024 behind us, #biotech fundraising seems to be returning to a more regular pace. ✅ Here's what our tracker found this week: 🇺🇸 Dyne Therapeutics | $345.1 million public offering | muscle disease therapies | clinical in myotonic dystrophy type 1 🇺🇸 Praxis Precision Medicines, Inc. | $150 million public offering | precision medicine | clinical in pediatric patients with early-onset SCN2A developmental and epileptic encephalopathy | Read more 🇺🇸 Myrobalan Therapeutics | $24 million series A | CNS disease therapies | IND-enabling in multiple sclerosis, Alzheimer’s disease and amyotrophic lateral sclerosis 🇩🇪 DISCO Pharmaceuticals GmbH | EUR 20 million ($21.75 million) seed | drug discovery | map of small cell lung cancer surfaceome completed 🇨🇭 STALICLA | $17.4 million series B | neurodevelopmental disorder-specific precision medicine platform | phase 1b in autism spectrum disorder 🇫🇮 DelSiTech Ltd | €10 million ($10.88 million) | drug delivery | clinical in chronic hepatitis B 🇺🇸 Cyrano Therapeutics | $9 million series B | phase 2 in post-viral smell loss 🇨🇦 XORTX Therapeutics Inc. | $2 million public offering | orphan disease indications | phase 2 in polycystic kidney disease 📌 Subscribe to Labiotech.eu to receive all our biotech updates.

𝗙𝗿𝗶𝗱𝗮𝘆 𝗤𝘂𝗶𝗰𝗸-𝗙𝗶𝗿𝗲 🔥 Santa Ana Bio, Inc., a precision immunology company has announced that it has secured with $𝟭𝟲𝟴 𝗺𝗶𝗹𝗹𝗶𝗼𝗻 𝗶𝗻 𝗦𝗲𝗿𝗶𝗲𝘀 𝗔 𝗮𝗻𝗱 𝗕 𝗳𝘂𝗻𝗱𝗶𝗻𝗴 bringing it out of stealth. The company targets autoimmune and inflammatory diseases using proteomic, transcriptomic, and genomic approaches to precisely attack disease-specific cells Rapport Therapeutics closes 𝗜𝗣𝗢 𝗮𝘁 $𝟭𝟳𝟰𝗠 raised for its discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders Bright Peak Therapeutics back by J&J secured $𝟵𝟬𝗺 to advance immunoconjugate programme. The money will assist in the advancement into a Phase I/IIa clinical trial for the treatment of solid tumours; claiming their drug will be the first immunoconjugate of its kind to enter the clinic. #Biotech #BiotechNews #Funding #MasonHarding

🔲 F1000 Media: Coya Therapeutics, Inc. Accelerates Alzheimer’s Research with Key Collaborations Coya Therapeutics is making waves in the biotech industry with its recent advances in neurodegenerative disease treatment. In the last two months, the company has been focusing on expanding research and development efforts, particularly around #Alzheimer’s and other neurodegenerative diseases. 🔳 Collaboration with Dr. Reddy’s Laboratories: Coya Therapeutics is leveraging its partnership with Dr. Reddy’s Laboratories to enhance its flagship biologic, #COYA302. This dual-mechanism treatment for Alzheimer’s disease shows promising results in modulating the immune system, specifically targeting the inflammation that contributes to the progression of neurodegenerative disorders. 🔳 Presenting at Major Healthcare Conferences: In September and October 2024, Coya is scheduled to present its latest findings at several key conferences, including the Alzheimer’s Drug Discovery Foundation (ADDF) Summit. Their focus on innovative biologics and therapies designed to restore immune balance is set to change how the medical community approaches diseases like #Alzheimer’s, #Parkinson’s, and #ALS. 🔳 Advancing Neuroinflammation Research: These collaborations and conference presentations highlight Coya’s commitment to advancing science in neuroinflammation and regulatory T cell therapies. By combining forces with top industry players, Coya is positioning itself at the forefront of finding effective treatments for neurodegenerative diseases. #CoyaTherapeutics #AlzheimersResearch #Biotechnology #Neurodegeneration #TregTherapies #Coya302 #F1000Media #DrReddys #ADDF #Neuroinflammation #Parkinsons #ALS #HealthcareInnovation

Modiblast Pharma GmbH is ready to advance into the clinical development phase with novel Dendritic Cell Therapies for liquid cancers. The focus is to target the core issue in acute myeloid leukemias (AML) and Myelodysplastic Syndromes (MDS): the extremely high rate of relapses after successful initial therapy. The Modiblast approach (3 patents granted) combines immunomodulators to induce blast cells to differentiate into leukemia-specific dendritic cells (DCleu) in the patient. This triggers both innate and adaptive immune cells in blood and tissue to kill remaining or recurring blasts and generates memory cells. Contrary to e.g. CAR-T there is no need to identify and select specific target molecules. And it doesn’t require complicated and expensive ex vivo cell extraction and preparation procedures and GMP facilities. Our long-term goal is to provide an easy-to-use self-administered drug that can stabilize remissions or halt progression of the diseases. This therapy may also normalize thrombocyte/neutrophil counts. The next step of clinical development is a Phase 1a/2b study which recently has passed BfArM scientific advice. Meet Modiblast Pharma GmbH @ #Sachs_BEF More Info @ https://lnkd.in/d7zEuKym #BigPharma #Dealmakers #PharmaIndustry #BiotechInEuropeForum #LifeSciences #Biotech #BioPharma #Partnering #Investment #Startups #Oncology #Neurology #Genomics #Immunotherapy #CNS #Autoimmune #Cardiovascular #BiotechIndustry #BioTechInvestment #Innovation #InvestmentForum #BiotechConference #EuropeanBiotech #SachsAutumnLifeSciencesWeek #SALSW

An estimated 11m people were living with #Parkinson’sdisease in 2023, making it the second most common neurodegenerative disease and yet currently the only treatments available only provide symptomatic relief and are unable to halt or reverse disease progression.   On #WorldParkinson’sDay, we are pleased to recognise the companies within SV's Dementia Discovery Fund (DDF)'s portfolio developing innovative therapeutic solutions to this devastating disease; Amphista Therapeutics Limited is unlocking new possibilities by using its CNS-penetrant protein degrader molecules with class-leading physicochemical properties, Cerevance is harnessing its proprietary NETSeq platform to identify novel, genetically validated targets for CNS diseases and expects to have data from its Phase 2 monotherapy study in patients with early Parkinson's later this year, DDF-created Endlyz UK Limited is developing small molecules to restore endo-lysosomal function and reverse neurodegeneration in PD and other dementias and Nitrase Therapeutics is developing an antibody that targets pathological nitrated alpha synuclein, one of the proteins implicated in Parkinson’s disease progression.

After decades of research, there remains a dearth of impactful treatments for complex, neurological diseases like Alzheimer’s, Parkinson’s and Rett syndrome. Lucy Therapeutics, who today announced $12.5 million in additional funding co-led by Engine Ventures and Safar Partners, with new participation from Bill Gates, Parkinson's UK, and The Michael J. Fox Foundation for Parkinson's Research, believes we must move away from the siloed, genetic-only approach to studying neurological disease to truly break through. LucyTx seeks to understand the mitochondrial roots of complex diseases, ultimately identifying new drug targets by analyzing a wide range of disease drivers including environmental and genetic factors. With three drug discovery programs already in its pipeline, we look forward to seeing what’s next for the company. https://lnkd.in/eq8m_DFA

An estimated 11m people were living with #Parkinson’sdisease in 2023, making it the second most common neurodegenerative disease and yet currently the only treatments available only provide symptomatic relief and are unable to halt or reverse disease progression.   On #WorldParkinson’sDay, we are pleased to recognise the companies within SV Health Investors’ Dementia Discovery Fund (DDF)'s portfolio developing innovative therapeutic solutions to this devastating disease; Amphista Therapeutics Limited is unlocking new possibilities by using its CNS-penetrant protein degrader molecules with class-leading physicochemical properties, Cerevance is harnessing its proprietary NETSeq platform to identify novel, genetically validated targets for CNS diseases and expects to have data from its Phase 2 monotherapy study in patients with early Parkinson's later this year, DDF-created Endlyz UK Limited is developing small molecules to restore endo-lysosomal function and reverse neurodegeneration in PD and other dementias and Nitrase Therapeutics is developing an antibody that targets pathological nitrated alpha synuclein, one of the proteins implicated in Parkinson’s disease progression.

EvlaBio AG is a life science startup dedicated to the development of first-in-class therapeutics in the cardiovascular and cardiorenal space. The lead asset is a therapeutic monoclonal antibody (mAb) targeting the FGF23/FGFR4 pathway for the treatment of left ventricular hypertrophy (LVH) and heart failure with preserved ejection fraction (HFpEF) in the setting of chronic kidney disease (CKD). LVH and HFpEF occur in CKD patients as a consequence of FGF23/FGFR4 overdrive. Hence, blocking the FGF23/FGFR4 interaction has the potential to prevent cardiac hypertrophy and ameliorate heart failure in patients with CKD. The serviceable obtainable market of patients with LVH due to FGF23/FGFR4 overdrive ranges between 5 and 6 M in the seven major markets, representing a substantial commercial opportunity. Based on its underlying mechanism of action, the EvlaBio approach is expected to be hemodynamically neutral. This is a critical differentiating feature from currently available treatment options. With respect to modality, the EvlaBio will be the first biologic developed for this indication, and it has the potential to be a first in class and first in indication therapy. We also have a biomarker strategy leveraging specific features of target biology in place, ensuring effective clinical trial design. Meet EvlaBio @ #Sachs_BEF More Info @ https://lnkd.in/d7zEuKym #BigPharma #Dealmakers #PharmaIndustry #BiotechInEuropeForum #LifeSciences #Biotech #BioPharma #Partnering #Investment #Startups #Oncology #Neurology #Genomics #Immunotherapy #CNS #Autoimmune #Cardiovascular #BiotechIndustry #BioTechInvestment #Innovation #InvestmentForum #BiotechConference #EuropeanBiotech #SachsAutumnLifeSciencesWeek #SALSW

Vivet Therapeutics have announced the financing of €4.9 million received from the French government to advance the development of a #genetherapy for the treatment of cerebrotendinous xanthomatosis (CTX), a rare neurodegenerative disease. This funding is from the “Innovations in biotherapies” framework of the France Health Innovation Plan 2030 and specifically the acceleration strategy Biotherapies – Bioproduction in innovative therapies. Coordinated by the French Health Innovation agency, the funding, will be distributed over a three-year period and operated by Bpifrance.

EvlaBio AG is a life science startup dedicated to the development of first-in-class therapeutics in the cardiovascular and cardiorenal space. The lead asset is a therapeutic monoclonal antibody (mAb) targeting the FGF23/FGFR4 pathway for the treatment of left ventricular hypertrophy (LVH) and heart failure with preserved ejection fraction (HFpEF) in the setting of chronic kidney disease (CKD). LVH and HFpEF occur in CKD patients as a consequence of FGF23/FGFR4 overdrive. Hence, blocking the FGF23/FGFR4 interaction has the potential to prevent cardiac hypertrophy and ameliorate heart failure in patients with CKD. The serviceable obtainable market of patients with LVH due to FGF23/FGFR4 overdrive ranges between 5 and 6 M in the seven major markets, representing a substantial commercial opportunity. Based on its underlying mechanism of action, the EvlaBio approach is expected to be hemodynamically neutral. This is a critical differentiating feature from currently available treatment options. With respect to modality, the EvlaBio will be the first biologic developed for this indication, and it has the potential to be a first in class and first in indication therapy.  We also have a biomarker strategy leveraging specific features of target biology in place, ensuring effective clinical trial design. Meet EvlaBio AG @ #Sachs_ELSF More Info @ https://lnkd.in/dQWhKYkV #ELSF2024 #LifeSciences #Biotech #BioPharma #Partnering #Investment #Startups #RisingStars #Oncology #Neurology #Genomics #Immunotherapy #CNS #Autoimmune #Cardiovascular #BiotechIndustry #BioTechInvestment #Innovation #InvestmentForum #SachsSpringLifeSciencesWeek #SSLSW